Literature DB >> 6829958

Suppression of noxiously evoked WDR dorsal horn neuronal activity by spinally administered morphine.

E Homma, J G Collins, L M Kitahata, M Matsumoto, M Kawahara.   

Abstract

The present study was carried out in order to examine the ability of spinally administered morphine to suppress noxiously evoked activity of wide-dynamic-range (WDR) neurons in the dorsal horn of the spinal cord in decerebrate, spinal cord-transected cats. All cells (n = 25) responded maximally to high-intensity noxious heat stimulation (51 degrees C) and were classified as wide dynamic range neurons. The spinal administration of 0.1 mg of morphine caused a significant reduction of noxiously evoked activity but did not significantly change spontaneous activity. The 0.25-mg dose caused a significant reduction of both types of activity. Thirty minutes after spinal administration, 0.1 mg of morphine caused a 27% reduction of spontaneous activity and a 43% reduction of noxiously evoked activity. The 0.25-mg dose reduced spontaneous activity by 44% and the evoked activity by 70%. Naloxone partially reversed the morphine-induced neuronal suppression. In addition, in the four neurons in which it was tried, spinally administered epinephrine was found to further suppress the remaining neuronal activity following the spinal morphine effect. These results demonstrate for the first time that spinally administered morphine is capable of suppressing noxiously evoked activity of wide-dynamic-range neurons in the dorsal horn of the spinal cord. They also demonstrate the dose-dependent nature of this effect and the potential importance of the interaction between morphine and adrenergic agonists in blocking information about noxious events. This information provides a probable mechanism of action for spinal opiate analgesia.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6829958     DOI: 10.1097/00000542-198303000-00005

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  7 in total

Review 1.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

2.  Development of a spontaneously active dorsal root ganglia assay using multiwell multielectrode arrays.

Authors:  Kim Newberry; Shuya Wang; Nina Hoque; Laszlo Kiss; Michael K Ahlijanian; James Herrington; John D Graef
Journal:  J Neurophysiol       Date:  2016-04-06       Impact factor: 2.714

3.  Comparison of intensity-dependent inhibition of spinal wide-dynamic range neurons by dorsal column and peripheral nerve stimulation in a rat model of neuropathic pain.

Authors:  F Yang; Q Xu; Y-K Cheong; R Shechter; A Sdrulla; S-Q He; V Tiwari; X Dong; P W Wacnik; R Meyer; S N Raja; Y Guan
Journal:  Eur J Pain       Date:  2014-01-06       Impact factor: 3.931

Review 4.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

5.  Mu-opioidergic modulation differs in deep and superficial wide-dynamic range dorsal horn neurons in mice.

Authors:  Qian Xu; Wei-Yan Li; Yun Guan
Journal:  Neurosci Lett       Date:  2013-06-04       Impact factor: 3.046

6.  Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects.

Authors:  W J Martin; A G Hohmann; J M Walker
Journal:  J Neurosci       Date:  1996-10-15       Impact factor: 6.167

7.  Pharmacokinetic analysis of ziconotide (SNX-111), an intrathecal N-type calcium channel blocking analgesic, delivered by bolus and infusion in the dog.

Authors:  Tony L Yaksh; Annelies de Kater; Robin Dean; Brookie M Best; George P Miljanich
Journal:  Neuromodulation       Date:  2012-07-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.